The coronavirus disease 2019 (COVID-19) pandemic has turned pregnant women’s healthcare into a worldwide public health challenge. Although initial data did not demonstrate pregnancy as a more susceptible period to severe outcomes of acute severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection, there are an increasing number of reports showing that not only pregnant women might be at significantly higher risk than non-pregnant women by COVID-19 but also the fetus. These findings may be related to adaptive changes that occur during pregnancy, such as the reduction in the residual respiratory capacity, the decrease in viral immune responses, and the increased risk for thromboembolic events. Additionally, despite the SARS-CoV-2 vertical transmission evidence being uncommon, maternal illness severity might reflect serious perinatal and neonatal outcomes. Thus, protecting the maternal–fetal dyad against COVID-19 is critical. Even though pregnant women initially were excluded from vaccine trials, several studies have provided safety and efficacy of the overall vaccine COVID-19 platforms. Vaccination during pregnancy becomes a priority and can generate benefits for both the mother and newborn: maternal neutralizing antibodies are transmitted through the placenta and breastfeeding. Moreover, regarding passive immunization, human milk contains other bioactive molecules and cells able to modulate the newborn’s immune response, which can be amplified after the vaccine. Nonetheless, many issues remain to be elucidated, considering the magnitude of the protective immunity transferred, the duration of the induced immunity, and the optimal interval for pregnant immunization. In this review, we assessed these unmet topics supported by literature evidence regarding the vaccine’s immunogenicity, pregnancy immune heterogeneity, and the unique human milk antiviral features.
The high variability of human leukocyte antigen (HLA) genes results in each molecule having distinct antigenic peptide binding capacities, potentially influencing the immune response to SARS-CoV-2. This study aimed to investigate associations between HLA class I (A, B) and class II (DRB1) polymorphisms and COVID-19 severity in a South Brazilian population, and to evaluate the binding affinity of alleles to viral peptides. A cross-sectional study included 503 unvaccinated patients with RT-qPCR-confirmed COVID-19: 145 non-severe, 129 severe, and 229 critical. HLA typing was performed using PCR-SSO and Luminex™ technology. The DRB1*11 allelic group was significantly associated with protection against severe and critical cases, while DRB1*15 was associated with increased risk; both remained significant after Bonferroni correction. Other allelic groups were associated with disease outcomes but lost significance after correction: B*49 and B*08 (risk); and B*37, B*50, and A*03 (protection). In silico analysis revealed that the DRB1*15 allele group showed a higher proportion of strong binders, mostly from non-structural proteins, while DRB1*11:01 binders, though fewer in number, were concentrated in the M protein. These results suggest functional differences in antigen presentation and reinforce the relevance of class II HLA, particularly DRB1, in modulating COVID-19 severity.
Despite the effectiveness of antiretroviral therapy (ART) in suppressing HIV‐1 replication and reducing morbidity, viral eradication remains unachievable due to the persistence of latent reservoirs, particularly within memory CD4 + T cells. Dendritic cell (DC)‐based immunotherapeutic approaches have emerged as potential strategies to enhance antigen‐specific immune responses against HIV‐1. In this context, alpha‐type‐1 polarized DCs (αDC1) are notable for their capacity to produce interleukin‐12p70 (IL‐12p70) and induce robust Th1 and cytotoxic T lymphocyte (CTL) responses. However, clinical outcomes have been inconsistent, often influenced by host factors and methodological variability in DC generation and antigen delivery. The high genetic diversity of HIV poses challenges for vaccine development, whereas conserved regions such as gag and pol represent promising immunogenic targets. The present study aimed to evaluate a set of previously identified conserved HIV‐1 peptides for their ability to stimulate HIV‐specific T cell responses when presented by αDC1 in vitro in coculture assays using samples from a Brazilian cohort, as part of a preparatory phase for a clinical trial. For this purpose, monocytes were differentiated into αDC1 using IL‐4 and GM‐CSF. On Day 5, the cells were pulsed with 14–21mer HIV‐1 peptide pools (gag and pol) and matured by the addition of IFN‐α, IFN‐γ, IL‐1β, and TNF‐α. After 48 h, αDC1 were harvested and cocultured with autologous T cells for 6 or 20 days. Pulsed‐αDC1 were able to induce immune responses through the production of IFN‐γ in T cells, with the subpopulation of effector memory CD4 + T cells ( TEM ) being responsible for the production of this cytokine after reexposure to the HIV antigens.